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Abstract 
Endothelial damage and dysfunction are implicated in cardiovascular pathological 
changes and the development of vascular diseases. In view of the fact that the 
spontaneous endothelial cell (EC) regeneration is a slow and insufficient process, it 
would be of great significance to explore alternative cell sources capable of 
generating functional ECs to repair damaged endothelium. Indeed, recent 
achievements of cell reprogramming to convert somatic cells to other cell types 
provide new powerful approaches to study endothelial regeneration. Based on 
progress in the research field, the present review aims to explore the strategies and 
mechanisms of generating endothelial cells through reprogramming from somatic 
cells, and to examine what this means for the potential application of cell therapy in 
the clinic. 
Key Words: Stem cells, cell reprogramming, endothelial cells, iPS cells, endothelial 
regeneration, atherosclerosis 
 
Introduction 
Vascular endothelial cells (ECs) array the most inner layer of the entire circulatory 
system, from the largest arteries and veins to the smallest capillaries and serve as a 
semi-selective and non-adherent interface between blood and the underlying cells of 
the vessel wall such as smooth muscle cells (SMCs), pericytes and connective 
tissues. ECs play a key role in critical vascular functions, such as permeability, 
interaction with circulating platelets and leukocytes, regulation of vascular tone and 
growth. EC dysfunction or damage precede the development of many vascular 
pathological conditions such as peripheral vascular disease, hypertension and 
atherosclerosis.1 Chronic exposure to cardiovascular risk factors such as diabetes, 
hyperlipidaemia or smoking, compromises the integrity of the endothelium and 
atherosclerosis occurs in the vessel wall. When the disease progresses severely, a 
treatment with angioplasty is routinely used in clinic. However, there is a risk of 
thrombosis due to the loss of ECs. The regeneration of endothelium in this case is a 
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slow process and there is currently no effective drug or gene therapy to promote it. 
Recently, efforts to achieve endothelial repair have shifted to stem cell–based 
approaches. Endothelial progenitor cells (EPCs) and pluripotent embryonic stem cells 
(ESCs) can be isolated, easily expanded and then differentiated into EC to be used 
for stem cells-based cellular therapies. 2-8 
A third source of stem cell that has great potential for regenerative medicine is the 
induced pluripotent stem (iPS) cells. IPS cells are pluripotent cells engineered from 
terminally differentiated somatic cells through a process called reprogramming. IPS 
cells exhibit the cellular characteristics that are highly similar to ESCs. 9-11 However, 
iPS cells avoid the ethical and immunological issues associated with the application 
of ESCs. Moreover, iPS cells can be generated and individualised for patient-specific 
therapies, disease modelling and drug screening. IPS cells are capable of 
differentiating into all cardiovascular cells including ECs, vascular mural cells, SMCs, 
and cardiomyocytes and therefore have a great potential for vascular regeneration. 
Nevertheless, this strategy is time consuming and raises tumour-forming hazards. To 
avoid issues associated with iPS cells, researchers start to explore direct cell fate 
conversion between two differentiated cell types without passing through the 
pluripotent state. This strategy called direct reprogramming opens up an exciting new 
area of research for cell based therapy. 
In the present review, we aim to explore the recent progress in cell reprogramming 
technique for endothelial regeneration, to discuss the mechanisms involved, and to 
highlight the potential clinical application. 
 
Vascular Endothelial Cells and Endothelial Functions 
 
Blood vessels are composed of three layers: the innermost is the tunica intima, which 
is composed of a single continuous layer of endothelial cells and mediates the 
exchange of nutrients and cells with the circulation. Surrounding the intima is the thick 
layer of smooth muscle cells composing the tunica media, which is responsible for the 
maintenance of the vessel tone and elasticity. Finally, adventitia is the external layer 
mainly composed of fibroblasts and connective tissue and incorporating the vasa 
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vasorum, the small network of vessels that provides oxygen and nutrients to the cells 
in the vessel wall. Vessels within the microvascular system (i.e. capillaries and 
venules) are formed by contractile cells called pericytes that wrap around the EC 
layer. 12 ECs are key components for maintaining the function of the vessels. ECs are 
actively involved in regulating endothelium permeability, modulating vascular tone, 
regulating blood coagulation, and many other biological processes. 
The integrity of the endothelium is the foundation of vascular homeostasis.  The 
cell-cell junctional structures, which link EC with each other to form a continuous 
monolayer, profoundly contribute to the regulation of permeability and the 
maintenance of the endothelium integrity. Furthermore, EC junctions actively 
participate in transferring intercellular signals between adjacent cells. EC junctions 
are formed by transmembrane adhesive proteins linked to specific cytoplasmic and 
cytoskeletal molecules. 13  
Endothelium regulates vascular tone through secreting EC-derived vasodilators 
including NO, prostacyclin and other factors. These EC-derived factors mediate the 
relaxation of SMCs to achieve vasodilation. NO is recognised as the primary factor for 
vasodilation which is synthesised in ECs by eNOS and that is dependent on its 
cofactors including free calcium (Ca2+) and L-arginine. 14 In addition to the modulation 
of vascular tone, NO also has other vessel-protective roles including regulating the 
growth of local cells, inhibiting the aggregation and adhesion of inflammatory cells 
and platelets to endothelial surface. 15  
Healthy ECs possess anticoagulant and antithrombotic functions to keep the vascular 
patency. Blood coagulation is prevented by ECs through synthesising and displaying 
inhibitors for tissue factor pathway and thrombin. ECs also express molecules for 
protein C activation which can demolish certain clotting factors and inhibits 
coagulation. 16 ECs can physically separate the interaction of platelets with collagen 
which can activate platelets. ECs also secrete anti-platelet molecules like prostacyclin, 
NO and prostaglandin-E2 to inhibit the adhesion and activation of platelets on the 
endothelial surface. 17 Under physiological condition, endothelium prevents the 
inflammatory cells adhesion by failing to express adhesion molecules that mediate 
leukocytes attachment.   
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Endothelial Dysfunction in Vascular Diseases 
 
The dysfunction of the endothelial monolayer is the key initiation event of vascular 
diseases caused by a variety of stimuli including hypertension, diabetes, 
dyslipidaemia, oxidative stress and others. Endothelial dysfunction is characterised 
by leukocytes recruitment and platelet aggregation, increased permeability, thrombus 
formation, and impaired endothelium-mediated vasodilation. The expression of 
surface adhesion molecules are changed within the injured ECs which initiate the 
recruitment of blood leukocytes and platelets. In parallel, the endothelium 
permeability and the sub-endothelial extracellular matrix composition are altered to 
permit the penetration and accumulation of leukocytes and oxidised LDL particles. 18 
The NO synthesis capacity of ECs is also disturbed during atherosclerosis which 
impairs the endothelium-dependent vasodilation. Reduced NO synthesis occurs 
simultaneously with the increased generation of reactive oxygen species (ROS). 
Increased ROS bioavailability, together with the dysregulated oxidative stress, further 
damages the endothelial homeostasis. 19 To repair the injured endothelium and 
reconstruct normal endothelial physiological function is a major target for therapy 
against vascular disease.  
After endothelial dysfunction and denudation during vascular disease or treatment 
with angioplasty, endogenous resident ECs tend to proliferate and replace the injured 
endothelium. A number of studies from early years showed that local ECs participate 
in the repair of small areas of endothelial damage through migration and the repair of 
larger areas of damage through both proliferation and migration. 20  Recently, by 
transplanting wire-injured carotid artery segments from wild type mice into Tie2-GFP 
mice, Hagensen et al. demonstrated the resident ECs from the transplanted graft 
contribute to the re-endothelialisation of the lesion. 21  
Although the proliferation and migration of resident ECs represent a straightforward 
way for endothelial regeneration, it is a relatively slow and inefficient process. 22 In 
addition, with the effects of the cardiovascular risk factors, the adjacent ECs around 
injured endothelial area may also be in a dysfunctional state. The rejuvenation of ECs 
with normal function represents a significant target of vascular disease therapies. A 
number of different stem cell sources, that have been considered to contribute to EC 
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regeneration, potentially provide promising methods for regenerative medicine. In this 
review, we will focus on the generation of ECs through reprogramming technique. 
 
Induced Pluripotent Stem Cell and Endothelial Regeneration  
In 2006, Takahashi and Yamanaka first described the process of converting a lineage 
committed somatic cell back to the pluripotent state by simultaneously 
overexpressing four transcription factors Oct4, Sox2, Klf4 and c-Myc using viral 
vectors. 10 This Nobel Prize-winning hallmark study successfully reprogrammed 
mouse fibroblasts to a new type of pluripotent cell that highly resembled ESC in 
morphology, proliferation, gene expression and DNA methylation patterns. The newly 
generated cell population was termed “induced pluripotent stem cell” or iPS cell. 
Since then, iPS cells have been successfully generated from different somatic cell 
types with different combinations of reprogramming factors and various induction 
methods, which proved the universality of the concept of cell reprogramming. 23 
IPS cells have the potential to differentiate towards vascular cell lineages including 
ECs. ECs can be derived from iPS cells by using three approaches: embryoid body 
(EB) formation, coculture with feeder cells or defined chemical condition. In 2009, two 
groups first showed that ECs could be generated from human iPS cells. Choi et al. 
cocultured different human iPS cell lines with OP9 feeder cells for 8 days and then 
selected CD34- and PECAM-1- double positive cell population which could give rise 
to functional ECs after 7 days under endothelial-promoting culture conditions. 24 
Using a similar approach, Taura et al. cocultured human iPS cells with OP9 feeder 
cells for 10 days and observed the emergence of a VEGFR2-positive population with 
EC differentiation capacity. 25 Endothelial lineage-committed cells could also be 
derived from EB formed by iPS cells. 26 Most commonly, feeder-free culture systems 
with the combination of different culture substrates and chemical conditions have 
been successfully applied to induce ECs from iPS cells. 27  
IPS-ECs display similar features with mature ECs at the genetic and functional levels. 
A major advantage of using iPS cells as EC source is the abundant origins of iPS 
cells and the potential to generate patient individualised ECs that bypass the 
immunogenicity and ethical issues. IPS-ECs have been tested in peripheral vascular 
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disease mouse model to show their neoangiogenic capacity that led to the 
improvement of blood perfusion of ischaemic tissue. 26  
In spite of the fact that iPS cells start a new era of regeneration medicine, the 
tumourigenesis risk jeopardises their further clinical applications. The fact that many 
reprogramming factor cocktails contain oncogenes and many gene delivery methods 
use viral vectors raise the risk of tumour formation in vivo. 28 In addition, iPS cells 
exhibit more genetic and epigenetic instability compared to ESC due to the artificial 
reprogramming process. 29 Therefore, there is still a long way to go before the mature 
utilisation of iPS cells at the bedside. Cell direct reprogramming techniques to convert 
cell fate between two differentiated cell types without passing through the pluripotent 
state provide new possibilities for endothelial rejuvenation. 
 
Direct Cell Lineage Reprogramming and Endothelial Regeneration 
Presently, based on the use of transcription factors, there are two dominant 
reprogramming strategies to achieve direct cell-lineage conversion. One is through 
introducing various combinations of target cell type-specific transcription factors to 
directly drive cell lineage switch. In 2008, a case of in vivo study demonstrated the 
direct conversion of pancreatic exocrine cell to functional β-cell by injecting 
adenoviruses encoding three transcription factors Nng3, Pdx1, and Mafa into adult 
mice pancreas. 30 In 2010, via the overexpression of Gata4, Mef2c, and Tbx5, 
Srivastava’s group directly reprogrammed cardiac fibroblasts into functional 
cardiomyocytes in vitro. 31  The same group subsequently showed the in vivo 
reprogramming of murine cardiac fibroblasts into cardiomyocytes through 
intra-myocardial injection of the identical set of the three transcription factors. 32 In 
addition, a variety of reports provided evidence of directly reprogramming fibroblasts 
into other cell types including neurons, hepatocytes, etc. 33,34  
Another fast and efficient approach to modulate cell fate is based on the use of 
iPS-generating pluripotency factors such as Oct4, Sox2, Klf4, Nanog, etc to erase 
lineage particular signatures and reactivate repressed epigenetic network as a first 
step, but with shorter reprogramming time and different culture conditions to avoid the 
full induction of pluripotency. After this step, cells revert to an intermediate plastic 
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state which permits further manipulations towards the desired cell types. Short-term 
reactivation of reprogramming genes Oct4, Sox2, and Klf4 plus chemically defined 
media and cardio-inductive growth factor BMP4 converted embryonic and adult 
fibroblasts to functional cardiomyocytes. 35 During the conversion, the role of 
reprogramming factors is to erase the original cell identity via epigenetic mechanisms, 
instead of directly activate cardiomyocyte-specific genes.  
 
Direct Endothelial Reprogramming with EC-related Transcription Factors 
Ectopic overexpression of endothelial-related transcription factors has been applied 
to generate ECs from other somatic cell types. Ginsberg et al. first reported the direct 
reprogramming of human amniotic fluid-derived cells into ECs by ETS transcription 
factors ETV2, FLI1, and ERG1 together with TGF-β suppression. 36 ETS transcription 
factors are potent regulators for vascular development and angiogenesis and they 
regulate almost all typical endothelial markers. 37 EC-specific genes can be switched 
on within 4 days of ectopic expression of ETV2, FLI1, and ERG1 with TFG-β 
suppression. However, to establish stably proliferative EC population, a more precise 
temporal control on gene overexpression is needed. Recently, there were two 
important studies published, relative to the direct conversion of fibroblasts into ECs 
through the overexpression of selected endothelial related transcription factors. Han 
et al. converted mouse adult fibroblasts into ECs using a cocktail of five transcription 
factors: Foxo1, Etv2, Klf2, Tal1 and Lmo2. 38 All of these five factors play crucial roles 
in vascular development and endothelial maturation. Interestingly, authors from this 
study tried to use Etv2, Erg and Fli1 to reprogram mouse adult fibroblasts as shown in 
Ginsberg’s study. However, they did not observe any EC generation. On the contrary, 
including Erg or Fli1 into their reprogramming factor cocktail compromised EC 
reprogramming efficiency from fibroblasts. This finding indicates that for different cell 
types, specific optimisation of transcription factors combination and culture condition 
is required for successful endothelial reprogramming. Another study showed that 
solely overexpressing one ETS transcription factor ETV2 is sufficient to induce 
functional ECs from human adult fibroblasts. 39 The ETV2 expression level needs to 
be carefully controlled. Too low or too high ETV2 expressions both jeopardise the 
endothelial reprogramming efficiency from fibroblasts. In addition to ETV2 
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overexpression, the endogenous FOXC2 expression in the human adult fibroblasts is 
essential for ETV2 to induce EC reprogramming.  
 
Although using the target cell-specific transcription factors for direct cell lineage 
reprogramming represents a straightforward strategy, a major concern related to this 
method is that the original gene regulatory network of the starting cell type may be 
insufficiently inactivated.  Indeed, a recent study provided evidence to support this 
concern by comparing the gene expression patterns of various directly 
reprogrammed cell types with cells derived from pluripotent stem cells using a 
computational network biology platform named CellNet. Comprehensive analysis 
showed that directly reprogrammed cells tend to inadequately silence the expression 
programs of the starting cell population. 40 This suggests that using target cell-specific 
transcriptions factors to conduct the direct cell lineage conversion may fail to fully 
erase the identity of the starting cell type and result in the incomplete establishment of 
the gene regulatory networks of the target cell type.  
 
Direct Endothelial Reprogramming using iPS-generating Factors 
Short term overexpression of iPS-generating pluripotency factors has been used to 
induce the plasticity of somatic cells which leads to further differentiation towards 
endothelial lineage. By overexpressing Oct4, Sox2, Klf4 and c-Myc for 8 days, 
fibroblasts were reverted to an intermediate CD34-positive mesodermal progenitor 
state which could be further differentiated towards endothelial or smooth muscle 
lineages under different stimulating conditions. 41 The authors discussed that all four 
factors are requisite for the generation of CD34-positive cells. To remove any single 
factor leads to the failure of the mesodermal progenitor state induction. Converted EC 
is a mixed population of different endothelial subtypes including arterial, venous and 
lymphatic ECs. Studies from our lab showed that reprogramming human fibroblasts 
with OCT4, SOX2, KLF4, and c-MYC for 4 days generated partial-iPS (PiPS) cells 
with an upregulation of VEGFR2. PiPS cells have the ability to differentiate into both 
endothelial- and smooth muscle-like cells. 42,43 Functional ECs could be derived from 
PiPS cells after 6 days of differentiation in endothelial-inductive condition. Another 
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study reduced the transcription factors to Oct4 and Klf4 to obtain functional 
endothelial cells transdifferentiated from human fibroblasts. 44  
To use reprogramming factors, especially the oncogene c-MYC, as part of the 
protocol still raises tumourigenesis concerns. Although teratoma formation has not 
been observed in the in vivo experiments of any studies, the long term effect of using 
reprogramming factors is difficult to predict. Two recent papers discussed the direct 
reprogramming strategy using pluripotent factors induced transient pluripotent state 
at certain stage of the protocol. 45,46 Further studies need to clarify the exact roles of 
pluripotent factors in direct reprogramming and the transitions of cell identity during 
the transdifferentiation.  
 
Direct Endothelial Reprogramming using Small Molecules 
Beyond the use of transcription factors, recent studies exploited novel approaches 
including microRNAs (miRNAs), epigenetic regulators, signal pathways modulators 
and other small molecules to drive cell lineage conversion. Conditionally adding these 
small molecules into the transcription factors cocktail can boost the efficiency of cell 
fate switching. Furthermore, some combinations of the small molecules alone could 
drive direct lineage conversion without the ectopic overexpression of transcription 
factors. 47 A recent study demonstrated the transdifferentiation of human fibroblasts 
to endothelial cells using small molecule activators of toll-like receptor 3 (TLR3) 
combined with endothelial growth factors. 48 TLR3 agonist Poly I:C activates innate 
immune signalling which leads to increased epigenetic plasticity for cell fate 
manipulation. Histone modifications at the promoter regions of PECAM-1 have been 
observed during the fibroblast to EC conversion.     
 
Comparison of Different Stem Cell-based Strategies for EC Generation  
 
In the above sessions, we have discussed EC generation based on different 
reprogramming techniques (Fig.1). Because of the critical role that ECs play in 
cardiovascular physiological and pathological conditions, it is of great importance to 
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investigate and compare different cells sources and strategies that can regenerate 
functional ECs and further obtain therapeutic value. For now, three major stem cell 
types are regarded to be promising therapeutic options for endothelial regeneration: 
EPC, ESC, and iPS cell. In addition, the emergence of direct cell reprogramming 
provides novel powerful cell sources. The advantages and deficiencies of these cell 
types and their clinical application value are briefly summarised as follow (Table 1). 
 
Mechanisms involved in endothelial reprogramming 
 
From the ectopic overexpression of different sets of transcription factors, to the 
following modulation of signalling pathways and endothelial-inductive conditions, 
mechanisms from many aspects have been implicated in the endothelial 
reprogramming process (Fig.2). Signalling pathways regulating endothelial 
differentiation have been extensively reviewed before. 27,49-51 In this review, we focus 
on the mechanisms that more related to the generation of ECs through 
reprogramming.   
 
Epigenetic Modulations during Endothelial Reprogramming 
 
The conversion of cell type requires the fundamental resetting of the epigenome. The 
epigenetic signature of the starting cell type needs to be erased and a new epigenetic 
signature of the converted cell type needs to be established. The epigenetic 
modulations include chromatin reorganisation, DNA methylation changes, 
post-translational histone modification, etc. Many studies have shown the epigenetic 
changes along endothelial reprogramming. Furthermore, EC reprogramming can be 
achieved by targeting the epigenetic level instead of the transcriptional level. Using a 
small molecule of TLR3 agonist to active innate immunity could increase epigenetic 
plasticity and lead to the direct reprogramming of fibroblasts to ECs. 48 However, the 
detailed mechanisms and regulatory factors involved in the process are not clear yet.  
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DNA methylation profile is an important epigenetic signature of a committed cell type. 
Switching from one cell type to another requires the universal DNA demethylation 
towards the establishment of a new cell identity. 52 ECs converted from fibroblasts 
through CD34-positive mesodermal progenitor state using OCT4, SOX2, KLF4, and 
c-MYC lost the DNA methylation profile of fibroblasts 33. The promoter regions of 
VE-Cadherin and Tie2 were demethylated in the induced ECs derived from 
fibroblasts by Foxo1, Etv2, Klf2, Tal1 and Lmo2. 38  
Histone modifications play fundamental roles in controlling the expression of the 
genes. Histone repressive marker H3K27me3 at PECAM-1 and VE-Cadherin 
promoter regions were significantly decreased during the conversion of fibroblasts 
towards ECs using Oct4 and Klf4. 44 The histone active marker H3K4me3 was 
increased in the promoter regions of PECAM-1 together with the decrease of the 
H3K27me3 mark at the same regions during the reprogramming of fibroblasts 
towards ECs with TLR3 agonist. 48  
 
Cell Plasticity induced by Pluripotency Reprogramming Factors 
 
Since the establishment of reprogramming technique to generate pluripotent iPS cells 
from lineage-committed somatic cells, researchers have endeavoured to exploit the 
underlying molecular mechanisms. In general, the complex transcriptional and 
epigenetic changes of the whole genome occur during the reprogramming to reverse 
the differentiated cells back to the pluripotent state. Genome-wide analyses of the cell 
populations at different time points during the reprogramming process revealed three 
phases for successful iPS cell generation: initiation, maturation, and stabilisation. 53  
Each phase is characterised by the expression of a distinct group of genes. The initial 
phase is marked by a mesenchymal-to-epithelial transition. Interestingly, the 
signature genes associated with the maturation and stabilisation phases are not 
pluripotency regulators, but rather the genes related to cell cycle, cytoskeletal 
dynamics and signalling pathways. 54 Another study also used genome-wide 
analyses to show that there were two major gene expression changing waves. One 
occurred between 0-3 days, and the second wave happened between day 9 till the 
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end. 55 Genes responsible for proliferation and metabolic changes were activated and 
the genes related to fibroblast identity were suppressed during the first wave. The 
second wave was characterised by the expression of genes related to stem cell 
identity establishment and epigenetic remodelling. These cell population-based 
studies suggested that reprogramming is a multi-step process with transcriptome 
resetting. The existence of multiple phases along iPS cell generation, especially 
erasing the cell identity as a first step, provides more possibilities to adjust the iPS 
reprogramming strategy to apply on direct reprogramming by using iPS-generating 
factors.  
 
In order to understand the molecular mechanisms regulating EC reprogramming from 
other cell types using iPS-generating factors, it is important to understand the roles of 
the key reprogramming factors Oct4, Sox2, Klf4, and c-Myc at early stage of iPS cell 
generation. The clear function of these four transcription factors during cell 
reprogramming has not been clarified. In general, these four factors act as pioneer 
factors for remodelling the epigenome. They open up chromatin regions and bind to 
the promoters of a wide range of genes to guide further epigenetic modification. 56 
Interestingly, in addition to the genes that they usually regulate in ESCs, they also 
bind to the genes that are not occupied by these factors in ESCs. 57 This promiscuous 
binding phenomenon indicated that the roles of the reprogramming factors may be 
cell type dependent. Oct4, Sox2, and Klf4 collectively form a transcriptional network 
that associates with repressing somatic gene expression and upregulating pluripotent 
genes during reprogramming. c-Myc mainly acts as an transcriptional amplifier at all 
active promoters to enhance the kinetics and efficiency of reprogramming. 58 The fact 
that Oct4, Sox2, Klf4, and c-Myc are able to open chromatin and induce cell plasticity 
early in reprogramming support the direct lineage conversion strategy of transiently 
expressing these four factors to dedifferentiate the somatic cell back to an 
intermediate state followed by further differentiating the cells towards another lineage.  
KLF4 is particularly interesting when specifically considering the reprogramming 
towards vascular cell lineage. KLF4 has been shown to play a crucial role in 
regulating vascular cell development and function in addition to its reprogramming 
role and has been identified as an important transcription factor for both SMC and EC. 
KLF4 has been shown to directly bind to the promoter of VE-Cadherin in mature ECs 
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to improve cell barrier function. 59 Another study indicated that KLF4 plays a 
protective role in regulating the response of EC to inflammatory stimuli. 
Overexpressing KLF4 in ECs increases the expression of anti-inflammatory and 
anti-thrombotic factors including eNOS and thrombomodulin. 60 In c-Kit-positive 
vascular progenitor population derived from ESCs, Klf4 was shown to positively 
regulate their differentiation towards ECs. Overexpression of Klf4 in this population 
led to further upregulation of EC markers and knockdown of Klf4 resulted in an 
increase of SMC markers. 61 The above studies suggest that KLF4 may play an 
additional favourable role in promoting reprogramming towards the endothelial 
lineage. 
 
 
Mesenchymal-to-Epithelial Transition and Cell Reprogramming 
 
Among the studies related to the different phase of cell reprogramming, a biological 
process named Mesenchymal-to-Epithelial Transition (MET) has emerged to be a key 
event for the initial stage of somatic cell reprogramming.  
Based on the temporal changes of global gene expression, an important study in 
2010 divided the reprogramming of mouse embryonic fibroblast (MEF) to iPS cell into 
three main phases: initiation, maturation and stabilisation. Among which, the initiation 
stage was characterised by the MET driven by bone morphogenetic proteins (BMPs) 
signalling. 53 At the same time, another group demonstrated the requisite role of MET 
at early stage for successful mouse iPS cells generation. MET was regulated by the 
interactions with reprogramming transcription factors and TGF-β signalling. 62  
During the generation of human iPS cells from fibroblasts, the participation of MET 
was confirmed by a study that suggested that the reprogramming promoting function 
of miRNA-302 and miRNA-372 was partly acting through MET. 63 Later on, a 
comprehensive proteomics analysis of the whole course of reprogramming confirmed 
the existence of MET during early phase at protein level. 64 Till now, many studies 
have proved the occurrence of MET at early stage for successful somatic 
reprogramming in different cell systems.  
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In addition, recent studies indicated the involvement of MET during the early stage of 
direct cell lineage conversions, which suggested a more universal role of MET 
process in modulating cell-identity plasticity. Ectopic introduction of transcription 
factors Nr5a1, Wt1 and Dmrt1 into fibroblasts could initiate MET as a first step and 
finally convert the cells towards embryonic sertoli-like cells. 65 Another recent report 
on direct reprogramming of fibroblasts into induced cardiomyocytes demonstrated the 
involvement of MET. 66 Promoting MET through the suppression of Snai1 by miR-133 
could profoundly enhance the protocol efficiency and cell quality of converted 
cardiomyocytes. 
 
Notch Signalling Mediating Endothelial Differentiation 
The Notch signalling pathway participates in the regulation of diverse vascular cell 
function during embryonic and postnatal development. 67 The Notch signals usually 
function to drive the differentiation of the precursors between two alternative fates. 68 
For example, Notch signals determine the arterial-venous fate of ECs and the tip or 
stalk cells selection of ECs during angiogenesis.  
JAG1 is a Serrate/Jagged family transmembrane ligand for the Notch pathway 
containing multiple epidermal growth factor-like repeats. 69 JAG1, as the upstream 
ligand of the transmembrane receptors in the Notch pathway, plays a complicated 
role in orchestrating cell fate. The homozygous mutation of the Jag1 gene in mice 
causes early embryonic lethality due to extensive embryonic and yolk sac vascular 
defects. 70 The mutation of the JAG1 gene in humans leads to Alagille syndrome 
characterised by abnormal development of multiple systems during childhood. 71,72 
Vascular anomalies including pulmonary artery abnormalities, intracranial 
haemorrhages and other events, frequently occur in Alagille syndrome patients and 
account for a large portion of mortality, which reflects the important role of JAG1 
during human vascular development. 73  
The pro-angiogenic role of Jag1 has been shown using EC-specific and inducible 
knockout or overexpression in mice. Jag1 loss-of-function mutants exhibited reduced 
sprouting angiogenesis while Jag1 overexpression promotes sprouting angiogenesis. 
74
 Kwon et al. showed that Jag1-induced signals from the bone marrow 
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microenvironment are critical for the development of angiogenic ability of endothelial 
progenitor cells. 75 An interesting study recently demonstrated that JAG1 could 
subsequently activate KLF4 which induced the transdifferentiation of tumour cells into 
endothelial cells. 76 Nevertheless, there are reports of the opposite effect in other cell 
models. A recent study emphasised the role of JAG1 in promoting haematopoietic 
lineage over endothelial lineage specification during pluripotent stem cell 
differentiation. 77 It is conceivable that in different cell types and in response to 
different environmental cues, the JAG1 activated Notch pathway may delicately 
control a distinct regulation network which leads to altered consequences.  
HES5 is a common downstream target of the Notch pathway which belongs to the 
basic helix-loop-helix transcription factor family and is usually associated with neural 
cell differentiation. 78 One study suggested a role for HES5 in vascular development, 
as it might be a key positive mediator for the statin-induced differentiation of bone 
marrow stromal cells into ECs. 79 Another study has suggested that HES5 plays a 
part in promoting endothelial proliferation in response to endothelial injury during 
atherosclerosis. 80 This study also demonstrated that MicroRNA-126-5p promotes 
endothelial regeneration and limits atherosclerosis by suppressing the Notch inhibitor 
delta-like 1 homologue (Dlk1), which leads to the release of HES5 that was 
suppressed by Dlk1, allowing HES5 to play its role in endothelial repair.  
 
 
Potential Applications of EC Generated through Reprogramming 
 
One big advantage of using iPS cell or direct cell conversion technique to generate 
ECs is the use for patient-specific disease modelling and drug screening. Moreover, 
an exceptional advantage of direct lineage conversion over iPS cell is the potential 
application for direct in vivo lineage reprogramming for cell replacement therapy, 
which avoids the unstable long term of in vitro cell culture, tumour-forming risks and 
the technical obstacles for cell transplantation. For example, direct injection of 
transcription factors cocktail Gata4, Mef2c and Tbx5 into the infracted cardiac area 
could reprogram resident non-myocytes into cardiomyocyte-like cells with improved 
cardiac function. 32  The in vivo regeneration of functional insulin-producing 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
pancreatic β-cells from other types of pancreatic cells has been reported by several 
studies for their potential benefits for treating diabetes. 30,81,82 
Cell-based therapeutic angiogenesis is a recently arising approach to restore the 
blood perfusion in ischaemic tissue. Successful therapeutic angiogenesis depends on 
the transplanted cells to directly incorporate into the neovasculature as well as to 
secrete angiogenic growth factors. 83 This therapy is of special significance in treating 
peripheral artery disease (PAD) since current pharmacological and interventional 
revascularisation therapies are not beneficial enough. 84 However, researchers are 
still investigating the optimal starting cells to generate functional angiogenic cells. In 
the murine ischemia model of PAD, several studies demonstrated that direct 
reprogrammed ECs could efficiently engraft into local vasculogenesis of ischaemic 
tissue and profoundly improve the tissue perfusion. 38,39,42,44,48 Moreover, direct 
reprogramming without reversing to a pluripotent state prevents the risk of tumour 
formation.  
Reprogrammed ECs have the potential to become tissue specific ECs which provide 
interesting therapeutic value to target precise pathological conditions. This could be 
achieved through culturing the cells under in vitro or in vivo tissue specific 
microenvironment. In vitro co-differentiating ECs and neural cells from human iPS 
cells facilitates the reprogrammed ECs to acquire blood-brain barrier EC specification. 
85
 Neural cells provide relevant cues including Wnt/β-catenin signalling to specify the 
ECs towards a blood-brain barrier phenotype. Ginsberg et al. demonstrated that 
amniotic cells-derived ECs can be specifically educated into sinusoidal ECs to 
participate liver vasculature regeneration by intrasplenic transplantation. 29 Recent 
studies further clarify the molecular signatures to define tissue-specific ECs, which 
provide us more information to achieve EC specification through introducing 
transcription factor that regulate tissue specific EC identity. 86 
Tissue engineered vascular graft represents another promising direction for vascular 
regenerative medicine. In addition to direct transplantation to replace injured vessels, 
tissue engineered graft can also serve as a useful ex vivo model to study the 
mechanisms related to vascular cell or ECM behaviours. Based on a previous 
established protocol from our laboratory, functional vascular-resembling conduits can 
be generated by seeding the decellularised mouse aorta with human origin cells 
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using an ex vivo bioreactor circulation system. 43,87 Human fibroblast-derived ECs 
exhibited good ability to reendothelialise the decellularised graft. 42 
The proliferation and accumulation of SMC and fibroblasts following endothelial 
denudation/dysfunction profoundly contributes to the development of atherosclerosis 
and restenosis. Protocols for the direct conversion of fibroblasts into functional ECs 
may provide promising tools for in situ endothelial regeneration. However, the main 
obstacle to this future application is the lack of proper gene delivery technique aiming 
at the specific type of cell for in vivo reprogramming. A recent study demonstrated an 
in situ virus delivery method to specifically target vascular SMCs without effecting 
ECs by constructing a designated gene with EC enriched microRNA target 
sequences within the same vector. 88 By employing a similar strategy, it is possible to 
develop a method to specifically switch local fibroblasts or SMCs into the endothelial 
lineage to achieve autologous endothelium repair. 
 
Summary and Perspective 
Generating functional ECs from other somatic cell types with or without passing 
through a pluripotent state provides intriguing prospects for therapeutic application of 
vascular regeneration, especially to generate patient individualised cells that bypass 
the immunogenicity and ethical issues. However, the existing reprogramming 
methods to produce ECs are of various efficiencies. Therefore, further optimisation 
and standardisation of the methods are required to be able to produce ECs at clinical 
grade and scale. In addition, the underlying mechanisms of endothelial 
reprogramming need to be elucidated to facilitate the optimisation of the technique.  
The fast development in the field of computational biology provides new tools to 
analyse transcription factor combinations for efficient direct reprogramming. 89-91 A 
recently developed computational platform, Mogrify, predicted the sets of 
reprogramming factors to successfully convert keratinocytes into microvascular ECs 
based on the combined calculation of gene expression data and regulatory network 
information. 90 Novel bioinformatics approaches largely facilitate the development of 
cell lineage conversion protocols.    
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In the future, an efficient workflow could be to firstly use computational platform to 
predict the possible reprogramming strategy. Then to validate and optimise the 
reprogramming protocol at the bench to efficiently generate well characterised 
endothelial population. Finally the individualised endothelial population could be 
applied in downstream applications including vascular regenerative therapies, 
vascular disease modelling and drug screening (Figure 3).  
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Figure Legends 
 
Fig.1 Reprogramming strategies for endothelial generation from other 
types of somatic cells. 
Somatic cells can be reprogrammed towards the endothelial lineage with or 
without passing through a pluripotent state. (A) Ectopic overexpression of 
endothelial-specific transcription factors with endothelial-inductive conditions 
can directly reprogram somatic cells into ECs. (B) Using iPS-generating 
pluripotency transcription factors for a short term can switch the differentiated 
somatic cells to a intermediate plastic state. Then the partially reprogrammed 
cells can be further differentiated towards ECs. (C) Somatic cells can also be 
fully reprogrammed into iPS cells and then be stimulated into the endothelial 
fate.  
  
Fig. 2 Mechanisms involved in endothelial reprogramming. 
Different signalling pathways together with epigenetic and transcriptional 
regulations comprehensively modulate the reprogramming towards the 
endothelial lineage. Relevant signalling pathways include VEGF, BMP, 
NOTCH, TGF-β, FGF signalling pathways. Epigenetic modulations include 
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chromatin reorganisation, DNA demethylation, and post-translational histone 
modification. Transcriptional level is the wide-scale gene expression 
regulations induced by ectopically overexpressed transcription factors.  
 
 
Figure 3. An efficient workflow for endothelial reprogramming and 
applications. 
Based on the fast development in the field of computational biology, an 
efficient workflow for endothelial reprogramming can start with using 
computational platform to calculate the possible sets of transcription factors to 
achieve efficient reprogramming. Then the protocol can be verified and 
optimised at the bench. Finally, ECs generated through reprogramming from 
patients can be used for individualised cell therapy and tissue engineering, 
disease modelling and drug screening.  
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Table 1  Comparison of different stem cell-based strategies for endothelial regeneration 
  Cell Source Adult Stem Cells ESCs iPS Cells 
 
Somatic cells 
 
Origin 
Circulation, bone 
marrow or resident 
tissue 
Blastocyst of embryo 
Generated by 
reprogramming of 
somatic cells, usually 
fibroblast 
Many types of 
somatic cells: 
fibroblast, amniotic 
cell, etc 
EC 
generation 
Give rise to EC in 
response to specific 
stimulations and 
endothelial-
promoting culture 
conditions 
EB formation and 
subpopulation 
selection; culture with 
feeder cells or specific 
substrate under 
chemical defined 
endothelial-promoting 
condition 
Culture under chemical 
defined endothelial-
promoting conditions; 
EB formation and 
subpopulation 
selection 
Reprogrammed by 
specific transcription 
factor with 
endothelial-
promoting culture 
conditions 
Main 
Strengths 
·Autologous 
·Specific 
endothelial lineage 
committed 
·Clinical safety 
·Self-renewal 
·High proliferative 
capacity 
·Autologous 
·Self-renewal 
·Large number of cell 
sources 
·Autologous 
·Large number of cell 
sources 
·Simplicity and less 
time consuming 
Main 
Weaknesses 
·Ambiguous 
definition and 
isolation methods 
·Limited number 
·Limited replicative 
capacity 
·Ethical debate 
·Tumourigenesis risk 
·Immunological 
barriers 
·Unstable cell identity 
·Tumourigenesis risk 
·Time consuming 
·Unstable cell identity 
·Low efficiency 
·Various initial cell 
types 
·Unstable cell identity 
·Potential  
tumourigenesis risk 
Clinical 
Application 
A number of clinical 
trials proved the 
therapeutic 
benefits for 
revascularisation 
and remodelling 
No clinical trial data.  No clinical trial data No clinical trial data 
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Figure 1. Reprogramming strategies for endothelial generation from 
other types of somatic cells. 
Somatic cells can be reprogrammed towards the endothelial lineage with 
or without passing through a pluripotent state. (A) Ectopic overexpression 
of endothelial-specific transcription factors with endothelial-inductive 
conditions can directly reprogram somatic cells into ECs. (B) Using iPS-
generating pluripotency transcription factors for a short term can switch 
the differentiated somatic cells to a intermediate plastic state. Then the 
partially reprogrammed cells can be further differentiated towards ECs. (C) 
Somatic cells can also be fully reprogrammed into iPS cells and then be 
stimulated into the endothelial fate.  
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Figure 2. Mechanisms involved in endothelial reprogramming. 
Different signalling pathways together with epigenetic and transcriptional 
regulations comprehensively modulate the reprogramming towards the 
endothelial lineage. Relevant signalling pathways include VEGF, BMP, 
NOTCH, TGF-β, FGF signalling pathways. Epigenetic modulations include 
chromatin reorganisation, DNA methylation changes, and post-
translational histone modification. Transcriptional level is the wide-scale 
gene expression regulations induced by ectopically overexpressed 
transcription factors.  
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Figure 3. An efficient workflow for endothelial reprogramming and 
applications. 
Based on the fast development in the field of computational biology, an 
efficient workflow for endothelial reprogramming can start with using 
computational platform to calculate the possible sets of transcription 
factors to achieve efficient reprogramming. Then the protocol can be 
verified and optimised at the bench. Finally, ECs generated through 
reprogramming from patients can be used for individualised cell therapy 
and tissue engineering, disease modelling and drug screening.   
  
 
 
